Annexon (ANNX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.28
- Estimate
- -$0.24
- Surprise
- -15.2%
- Score today
- 4.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Annexon (ANNX) reported a wider loss than forecast — diluted EPS of -$0.28 against the -$0.24 estimate (a 15.2% shortfall).
Coverage in the report window
- Citizens Upgrades Annexon to Market Perform — benzinga, 2026-08-13
- Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate — benzinga, 2026-08-12
- Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial A — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates ANNX Sell at 4.8/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -15.2% surprise compares with a +3.0% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $15.29 vs price $3.93 — ratio 3.9×). Rejected, falling back to technical TP.
- Quality below floor (1.9 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.88
- Price target
- $5.48
- Stop
- $3.68
- Upside to target
- +41.2%
Risk check: RSI 20 — a level conventionally read as oversold; trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
ANNX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $743.2M
- P/E (fwd)
- -3.6
- 52-week range
- $2.50–$7.18
- Off 52-week high
- 46.0%
- RSI (14)
- 20
- Volume vs avg
- 1.63×
- Score today
- 4.8/10